The abrupt rise of the COVID-19 pandemic has enforced an optimistic impact on the global cancer stem cells market growth in 2020. Rising demand for treatment of metastatic stage cancer in the course of the COVID-19 pandemic is shoving the growth of the market
ByGina Wadas The Howard Hughes Medical Institute has awarded three pairs of Johns Hopkins PhD students and their mentors a 2020 Gilliam Fellowship for Advanced Study, which not only recognizes students who have the potential to be leaders in their fields, but also is designed to advance diversity and inclusion in the sciences.
DUBLIN, July 31, 2020 /PRNewswire/ -- The "Cell Reprogramming (iPSC Generation) / Direct Reprogramming Services and Products Market, 2020-2030" report has been added to ResearchAndMarkets.com's offering. The 'Cell Reprogramming (iPSC Generation)/Direct Reprogramming Services and Products Market, 2020-2030' report features an extensive study of the current market landscape and the future potential of cell reprogramming services and products in treating different chronic conditions
Reviewed by Emily Henderson, B.Sc.Jul 30 2020 Structures called primary cilia - which act like TV antennas for cells to detect signals - are present in fewer numbers in mice born with Fragile X syndrome, according to researchers from The University of Texas Health Science Center at San Antonio (UT Health San Antonio). Study results were published July 30 in the journal Stem Cell Reports
Company Announcement Copenhagen, Denmark; July 31, 2020 Genmab A/S (Nasdaq: GMAB) announced today that the European Myeloma Network (EMN) in collaboration with Janssen Research & Development, LLC (Janssen) reported positive results from the Phase 3 APOLLO (MMY3013) study of the subcutaneous (SC) formulation of daratumumab in combination with pomalidomide and dexamethasone (Pd) versus Pd alone as treatment for patients with relapsed or refractory multiple myeloma who have previously been treated with lenalidomide (an immunomodulatory drug) and a proteasome inhibitor (PI). The study met the primary endpoint of improving progression-free survival (PFS). Overall, the safety profile of daratumumab SC in combination with Pd was consistent with the safety profile for each therapy separately.
By the time the FDA approved Luxturna the pioneering gene therapy for an inherited retinal disease Henry Klassen had been researching and treating the group of diseases known as retinitis pigmentosa for more than 20 years. Spark Therapeutics success there had not just inspired a $4.3 billion takeover by Roche, it had also emboldened other biotechs pursuing a therapy that would deliver one of the genes tied to different variations of the disorder. Nightstar Therapeutics subsequently scored its own buyout with Biogen, and MeiraGTx recently posted early but exciting data on its J&J-partnered program.
Anand met with an unfortunate road accident and suffered spinal cord injury. He was suddenly propelled from the world of the able-bodied into the world of the disabled
In an industry where getting one drug developed from lab to clinic can cost hundreds of millions of dollars and decades of time, it helps when scientists can be thrifty and make use of substances that already exist. A global team of researchers has now done just that, by searching through one of the world's largest collections of already developed drugs to discover 21 potential treatments for COVID-19. We will need considerably more research to determine if any of these drugs can be used to help COVID-19 patients, but it's an excellent first step, bypassing some of the barriers for producing completely new drugs.
LONDON--(BUSINESS WIRE)--Technavio has been monitoring the cell viability assays market and it is poised to grow by USD 1.40 billion during 2020-2024, progressing at a CAGR of over 8% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment. Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19
Researchers at the UCLA Jonsson Comprehensive Cancer Center and UCLA School of Dentistryhave identified a potential new combination therapy to treat advanced head and neck squamous cell carcinoma, the most common type of head and neck cancer.
Recent Comments